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Abstract
OBJECTIVES—We assessed retention and predictors of attrition (recorded death or loss to 
follow-up) in antiretroviral treatment (ART) clinics in Tanzania, Uganda and Zambia.
METHODS—We conducted a retrospective cohort study among adults (≥18 years) starting ART 
during 2003–2010. We purposefully selected six health facilities per country and randomly 
selected 250 patients from each facility. Patients who visited clinics at least once during the 90 
days before data abstraction were defined as retained. Data on individual and programme level 
risk factors for attrition were obtained through chart review and clinic manager interviews. 
Kaplan–Meier curves for retention across sites were created. Predictors of attrition were assessed 
using a multivariable Cox-proportional hazards model, adjusted for site-level clustering.
RESULTS—From 17 facilities, 4147 patients were included. Retention ranged from 52.0% to 
96.2% at 1 year to 25.8%–90.4% at 4 years. Multivariable analysis of ART initiation 
characteristics found the following independent risk factors for attrition: younger age [adjusted 
hazard ratio (aHR) and 95% confidence interval (95%CI) = 1.30 (1.14–1.47)], WHO stage 4 
([aHR (95% CI): 1.56 (1.29–1.88)], >10% bodyweight loss [aHR (95%CI) = 1.17 (1.00–1.38)], 
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poor functional status [ambulatory aHR (95%CI) = 1.29 (1.09–1.54); bedridden aHR1.54 (1.15–
2.07)], and increasing years of clinic operation prior to ART initiation in government facilities 
[aHR (95%CI) = 1.17 (1.10–1.23)]. Patients with higher CD4 cell count were less likely to 
experience attrition [aHR (95%CI) = 0.88 (0.78–1.00)] for every log (tenfold) increase. Sites 
offering community ART dispensing [aHR (95% CI) = 0.55 (0.30–1.01) for women; 0.40 (0.21–
0.75) for men] had significantly less attrition.
CONCLUSIONS—Patient retention to an individual programme worsened over time especially 
among males, younger persons and those with poor clinical indicators. Community ART drug 
dispensing programmes could improve retention.
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Introduction
At the end of 2013, two-thirds of the estimated 35 million people globally living with HIV 
lived in sub-Saharan Africa (UNAIDS 2014). The number of people receiving antiretroviral 
treatment (ART) reached about 13 million in 2013. Sub-Saharan Africa achieved the 
greatest increase in ART coverage by reaching 9 million people, to about 37% coverage 
(UNAIDS 2014).
Corresponding with efforts to expand access to ART, there has been an increasing emphasis 
on attaining the high levels of retention and adherence necessary to achieve good clinical 
outcomes (Bangsberg et al. 2001; Hogg et al. 2002; Paterson et al. 2000; Nachega et al. 
2007). Retention is a critical determinant of adherence as patients must actively attend and 
participate in an ART care programme to receive their medication and to have their HIV 
clinical indicators monitored. Therefore, retention is a key indicator of programme quality 
(Giordano et al. 2007).
However, retention of patients in ART care remains a major challenge in sub-Saharan 
programmes. Results from a meta-analysis of 32 studies from programmes in sub-Saharan 
Africa showed that only 80% of patients started on ART were still in care after 1 year, 77% 
after 2 years and 72% after 3 years (Rosen et al. 2007; Fox & Rosen 2010). Loss to follow-
up (LTFU) and recorded death were the major causes of non-retention or attrition.
This study is the first component of a study examining retention and adherence to 
antiretroviral treatment among adults in three countries in sub-Saharan Africa. In this 
manuscript, we report the results of a retrospective medical chart review of adult ART 
patients from ART programme sites in Tanzania, Uganda and Zambia. The objectives of the 
study were to characterise the level of retention of patients on ART across multiple and 
different programme settings and to examine the relationship between individual and 
programme level characteristics and retention proportions.
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Methods
Design and study setting
A retrospective review of 4500 randomly selected medical records of ART patients from 
Tanzania, Uganda and Zambia was conducted. In each country, six sites were purposefully 
chosen to explore the impact that different programme characteristics may have on retention 
and adherence outcomes. This process resulted in study sites from different levels in the 
health system (ranging from primary/community-based health centres to national referral 
hospitals), from different types of health facilities (public sector, nongovernmental 
organisations (NGOs) or faith-based organisations), from urban-rural locations, and with 
different ART provision experiences and adherence strategies.
Inclusion criteria for site selection
Only sites with a minimum cohort size of 300 patients at the time of the protocol 
development (2006) were considered to fulfil the sample size requirement of 250 patients 
per study site. The site-selection process was conducted in consultation with country-
specific stakeholders including Ministries of Health (MOH) and United States Government 
(USG) partner organisations.
Inclusion and exclusion criteria for medical chart review
Patients who were at least 18 years of age at ART initiation, who initiated ART treatment (a 
combination of 3 antiretroviral drugs) at the site when free drugs were available and who 
had started ART at least 6 months prior to the data collection were included. Patients 
involved in other ART-related research were excluded.
Data collection and sampling
During the period from April to July 2010, a retrospective chart review of 4500 medical 
charts was conducted. During study start-up, the study team noticed that one facility in 
Tanzania consisted of two clinics that served adults on ART: an adult-only clinic and a 
family clinic where adults may seek care and treatment with their families. One hundred and 
25 patients from each of the adult-only and the family clinics were selected.
The study team worked with sites to develop sampling frames consisting of patient 
identification numbers (IDs). The study data analyst used these sampling frames to generate 
the 250 random numbers using a computerised random number generator in Microsoft Excel 
that indicated which patient charts would be abstracted. Data abstractors at each site pulled 
the randomly selected charts and screened them for eligibility. They recorded on a screening 
log if a chart was missing, ineligible, or eligible and abstracted. Replacement numbers were 
generated for those charts that were either ineligible or were missing after a minimum of 
three attempts to locate the chart over three consecutive weeks. Three sources of data were 
used: patient medical files, pharmacy logbooks and laboratory registers.
The study sites varied greatly in terms of how specific their sampling frames could be. Some 
sites had sampling frames consisting only of adult patients who had started on ART at that 
site. Other sites could only produce sampling frames with all patients (adults and children) 
Koole et al. Page 3
Trop Med Int Health. Author manuscript; available in PMC 2016 January 25.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
ever registered in HIV care. The ability to focus the sampling frame depended on the site’s 
data management systems.
Study teams underwent 1 week of data abstraction training and consisted of 2–3 data 
abstractors (mainly data entry staff and nurses from the facility) and one supervisor 
(typically the sister-in-charge or lead doctor managing the clinic). To better understand the 
programme factors related to retention and adherence, each study-site ART programme 
manager was interviewed about their ART clinic model in June 2011.
Data management and analysis
Data were double-entered in a study database using Epi-Data Entry 3.1 (EpiData 
Association, Odense, Denmark, Europe) at the in-country research organisation and then 
transferred to the central data office at FHI 360 for further cleaning and consistency checks. 
Consistency checks across the different sources of data were performed. Data analysis 
followed a statistical analysis plan, which was finalised before the completion of the study 
database. All analyses were performed using Stata versions 10 and 12 (Stata Corporation, 
College Station, TX, USA).
Attrition from the programme was defined as having no clinic, pharmacy or laboratory visit 
in the 3 months prior to data collection among patients whose charts did not indicate being 
transferred out or death. The primary outcome variable was time to discontinuation from the 
programme, defined as the time from start of first antiretroviral (ARV) drug treatment 
prescribed at the health facility until the last visit. The time to discontinuation was analysed 
using survival data methods (Altman & Bland 1998) where lost to follow-up and known 
deaths were considered the event of interest. Patients who were retained or transferred out 
were censored.
Retention proportions were estimated using the Kaplan–Meier method (Pocock et al. 2002). 
The analysis of risk factors for attrition was performed using Cox-proportional hazards 
regression, with a shared frailty term to account for clustering of outcomes at each site 
(Hougaard 1995). The proportional hazards assumption of predictors was assessed using 
graphical methods. A multiple Cox-regression model was constructed using a hierarchical 
approach. This approach included first individual level (P-value <0.1) and subsequently 
programme level (P-value <0.2) characteristics. Variables that were missing in more than 
30% of subjects or were not available at all sites or were present in a small minority of 
patients (<10%) were excluded from the multiple Cox-regression model. The model was 
simplified using Akaike’s Information Criterion, retaining predictors and clinically plausible 
interaction terms that increased model fit, with a penalisation for increasing model 
complexity (Collet 2003). Confidence intervals for effects were estimated using the Wald 
method and P-values using likelihood ratio tests. The final Cox-regression model was 
corrected for missing data in the predictors of attrition using Multivariate Imputation by 
Chained Equations (Little 1992; Royston 2004). Ten data sets were imputed with baseline 
predictors presumed to be missing at random, conditional on site and individual level 
predictors. Estimates were combined across imputed data sets according to Rubin’s rules 
(Little 1992).
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Sample size
A random sample of 250 ART-treated patients in each site was needed to allow the 
estimation of the retention proportion to be measured with a precision of 5% at site level, 
assuming the retention proportion at 6 months after ART initiation was at least 80%.
Ethics statement
The study was approved by the Institutional Review Board (IRB) of the U.S. Centers for 
Disease Control and Prevention (US), FHI 360’s Protection of Human Subjects Committee 
(US), the Muhimbili University of Health and Allied Sciences’ Research and Publications 
Committee (Tanzania), the National HIV/AIDS Research Committee (Uganda), the Uganda 
National Council for Science & Technology, the Tropical Diseases Research Centre’s Ethics 
Review Committee (Zambia), the Ministry of Health (Zambia), the Massachusetts General 
Hospital’s IRB (US) and Universitair Ziekenhuis Antwerpen (Belgium).
As the study was a retrospective chart review with minimal risks, and requesting consent 
would mean inclusion of only retained patients, the IRBs waived informed consent 
requirements to abstract participant charts. Written informed consent was required prior to 
interviewing the ART clinic managers.
Role of the funding source
This research was supported by a contract with FHI 360 by the U.S. Centers for Disease 
Control and Prevention (CDC) and the Health Resources & Services Administration 
(HRSA) with funds from the President’s Emergency Plan for AIDS Relief (PEFPAR). CDC 
provided technical input into the study design, data collection, data analysis, data 
interpretation and writing of the manuscript.
Results
A total of 7755 patient medical files were screened for eligibility at the participating sites. 
Of these, 1951 were ineligible, 1310 files were missing, and 4494 files were abstracted. 
During preparation for analysis, 84 duplicate files were excluded and another 22 were 
excluded for not meeting the eligibility criteria. One site in Zambia used an incorrect 
sampling frame (excluding patients who were known dead or lost to follow-up) which led to 
the exclusion of that site’s 241 patients, leaving 4147 patients for the final analysis.
Characteristics of the study population
Patients started ART between 2003 and 2010. The median age at ART initiation was 36 
years (interquartile range (IQR): 30–42), and 2670 (64.4%) were female. Three quarters of 
patients (3141 or 75.7%) had a baseline CD4 cell count, with the median CD4 cell count of 
134 cells/µl (IQR: 63–206). About half of patients (2197 or 53.0%) were in WHO stage 3 or 
4. A vast majority were started on one of the four traditional non-nucleoside reverse 
transcriptase inhibitor (NNRTI)-based regimens (3598 or 86.8%) and about 11% on a 
tenofovir-based regimen. Other characteristics, stratified by country, are presented in Table 
1.
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Characteristics of the patients whose charts were missing could not be described as the 
sampling frame consisted of patient identifiers only, and although date of birth and sex were 
recorded on the study screening logs, the information could not be collected for patients 
whose charts were missing.
Programme characteristics
Eighteen sites were included in the analysis, seven sites in Tanzania (the facility consisting 
of two different models of care was considered as two separate sites), six sites in Uganda 
and five sites in Zambia (one site was excluded because of using an incorrect sampling 
frame).
Half of the health facilities were government facilities. Non-governmental facilities were 
either faith-based or run by a non-religious non-governmental organisation (NGO). 
However, the level and type of health facilities were not evenly distributed across the three 
countries (with more primary health facilities and NGO-supported facilities in Uganda). 
Two-thirds of the sites were located in an urban setting. At the time of data extraction, 8 
sites had less than 2000 ART patients (range: 350–1967), 6 sites had between 2000 and 
4000 patients (range: 2095–3989) and 4 had more than 4000 patients on ART (range: 4807–
7471). Other characteristics, stratified by country, are presented in Table 2. Four 
programmes used community-based distribution of ARV drugs for stable patients. An 
overview of the modalities of community-based ARV distribution among the study sites is 
given in Table 3.
Retention proportions
The total period of follow-up by 4147 patients was 8378.5 years, with a median follow-up 
time of 1.7 years per person (IQR: 0.7–3.2). The retention proportion per site ranged from 
58.7% to 99.2% at 6 months, from 52.0% to 96.2% at 1 year, from 39.7% to 93.8% at 2 
years, from 32.7% to 90.4% at 3 years and from 25.8% to 90.4% at 4 years (Figure 1). 
Among the 1312 non-retained patients, 260 (19.8%) were known to have died. The 
remaining 1052 were lost to follow-up.
Predictors for attrition
During univariate analysis, significant associations for attrition were found for the following 
baseline characteristics: younger age (<30 years), male sex, further distance to the clinic, 
increasing years of clinic operation prior to ART initiation, a higher WHO stage, weight loss 
of >10% of body mass, wasting syndrome (weight loss of >10%, unexplained chronic 
diarrhoea >1 month and unexplained fever >1 month), a lower CD4 cell count, a lower total 
lymphocyte count, a lower haemoglobin count and a poorer functional status (Table 4).
All programme characteristics described in Table 2 were examined for association with 
attrition. Univariate analysis found that the level and type of health facility and the 
dispensing of ARV drugs at the community level were significant predictors of attrition. 
Participants from primary/community-based facilities experienced lower proportions of 
attrition. The same was true of faith-based and NGO-based facility participants. Facilities 
that had community-based ARV drug dispensing also experienced lower proportions of 
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attrition. We confirmed the effects of programme characteristics identified in the analyses 
across countries by assessing these effects in each country separately. During the stratified 
analysis by country, attrition was found to be significantly worse for governmental 
programmes in Tanzania and Zambia, but not in Uganda. Country was also associated with 
retention, with considerably less attrition found in Uganda compared with Tanzania and 
Zambia (Table 5). This was explained by the fact that three of the four sites with 
community-based ARV distribution were based in Uganda. Country was not formally 
considered as a site-level predictor as sites were not necessarily representative for the 
country as a whole, and including country as site-level predictor in the final model was not 
possible due to computational difficulties.
According to the predefined statistical analysis plan, distance to the clinic was not included 
in the multivariable Cox-regression model building because this variable was missing in two 
of the research sites. Other known predictors (Coetzee et al. 2004) excluded due to missing 
data include lymphocyte count, haemoglobin level (more than 30% missing data), oral 
candidiasis and wasting (present in <10% of the patients). The final multiple Cox-regression 
model, retaining only significant predictors and interactions, and correcting for missing data 
using multiple imputations, revealed that patients of younger age (<30 years) were at higher 
risk of attrition compared with older patients (≥30 years) [adjusted hazard ratio (aHR) for 
attrition, (95% confidence interval) (95% CI) = 1.30 (1.14–1.47)]. Patients with baseline 
WHO clinical stage of 3 or 4 had higher proportions of attrition compared with patients in 
stages 1 and 2 [aHR (95%CI) = 1.12 (0.95–1.35) and 1.56 (1.29–1.88), respectively]. The 
same was true for ambulatory (able to perform daily activities but not working) and 
bedridden (not able to perform daily activities) (WHO 2006) patients compared with 
working or active patients (able to perform usual work in or out of the house) [aHR (95%CI) 
= 1.29 (1.09–1.54) and 1.54 (1.15–2.07), respectively]. Patients with a loss of more than 
10% of body mass were at greater risk of attrition [aHR (95% CI) = 1.17 (1.00–1.38)]. The 
probability of attrition decreased proportionally with an increase in CD4 count [aHR 
(95%CI) = 0.88 (0.78–1.00) for every log (tenfold) increase].
At the programme level, community-based dispensing of ARV drugs was significantly 
related to less attrition [aHR (95%CI) = 0.55 (0.30–1.01) for women and 0.40 (0.21–0.75) 
for men] (Figure 2). This effect was particularly strong among males, with males and 
females at facilities that offered community-based distribution having similar attrition 
proportions [aHR (95%CI) = 0.95 (0.67–1.33)]. At sites without community distribution of 
ART, however, males had a higher attrition risk than female [aHR (95% CI) = 1.33 (1.18–
1.50)]. In addition, government run facilities compared with faith-based or NGO facilities 
were found to significantly predict attrition. No significant difference in retention was 
observed between government and faith-based or NGO facilities during the first year of 
operation. Attrition significantly increased over time in government facilities [aHR/year 
(95%CI) = 1.17 (1.10–1.23)], but not in faith-based or NGO facilities [aHR/year (95% CI) = 
1.03 (0.95–1.11)] resulting in an overall lower retention in government hospitals (Table 6).
A significant association was found between attrition and the number of randomly selected 
patients for whom the patient chart could not be located. Sites that had more missing records 
had less attrition (Table 5). Correcting the multiple Cox-regression model for the percentage 
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of selected records which were missing, by including this variable as a covariate, did not 
significantly change the effect estimates for the predictors included in the final model (data 
not shown).
Discussion
To date, most studies examining retention to ART care and treatment programmes focus on 
individual pre-ART clinical predictors. This study makes an important contribution to our 
understanding of ART retention by examining not only retention proportions across three 
countries and 18 study sites, but by going beyond individual baseline clinical predictors of 
attrition to examine the potential effect different programme characteristics may have on 
retention.
Overall, retention proportions varied widely both across countries and study sites (25.8% to 
90.4% at year 4 for example). These results are comparable to those from other studies in 
sub-Saharan Africa settings (Coetzee et al. 2004; Ferradini et al. 2006; Calmy et al. 2006; 
Weigel et al. 2012). These studies exemplify the challenges of defining retention in different 
settings and systematically accessing information in clinics with different data collection 
systems. Retention proportions are also greatly affected by the choice of LTFU definition 
(Shepherd et al. 2013).
Many of the baseline clinical characteristics predictive of attrition reinforce findings from 
other studies in sub-Saharan Africa, including younger age (<30 years), being male, having 
a higher WHO clinical stage, weight loss of >10% of body mass, a lower CD4 cell count and 
a poorer functional status (Coetzee et al. 2004; Ferradini et al. 2006; Calmy et al. 2006). 
These findings reaffirm the need for early identification of HIV-infected individuals and 
early initiation of ART. Increasing years of clinic operation, prior to when a patient initiated 
ART, was also an independent risk factor for attrition. This finding has been confirmed by 
other studies (Braitstein et al. 2006; Cornell et al. 2010). However, this effect was mainly 
observed in government facilities and was not significant in facilities run by faith-based 
organisations or NGOs. Rapid scaling-up may have considerably increased the workload for 
government health workers. This in turn may have compromised the organisation of services 
and quality of care provided. Faith-based and NGO facilities might have had better coping 
mechanisms and funding to increase staff levels and to adapt their services and monitoring/
tracking systems to the increasing numbers of ART patients. The association between 
attrition and older governmental programmes could also be partly explained by 
misclassification of LTFU which, in reality, consists of unreported (silent) transfer to care 
elsewhere (Geng et al. 2010). Initially, only hospital-based referral centres provided ART 
treatment, but in the setting of rapid scale-up, patients often transferred to closer lower-level 
facilities (Bedelu et al. 2007; Chan et al. 2010). Retention in an ART programme reflects a 
number of heterogeneous outcomes including mortality, LTFU and transfer of care (both 
silent and recorded). Geng et al. (2010) found that among 14 studies where outcomes in 
some patients LTFU were reported, about 50% were in care elsewhere. This finding 
highlights the importance of examining not only programme retention to specific ART 
clinics, but also retention to care regardless of where the services are rendered.
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The most important result of this study is that sites offering ARV drug dispensing in the 
community had significantly greater programme retention. Of particular importance was the 
effect of community-based ARV drug distribution on retention of men. As well established 
in the literature (Geng et al. 2010; Ferradini et al. 2006; Cornell et al. 2009), being male is 
an independent risk factor for attrition. However, in this study, this difference between the 
sexes was only observed in sites without community distribution of ARV drugs, where 
males were 30% more likely than females to experience attrition. In sites with community 
ARV drug distribution, attrition proportions among both men and women were about 50% 
smaller compared with women in sites without community distribution (the group with the 
lowest attrition).
Greater retention in community-based ART programmes may be due to fewer patients 
transferring out because many of the transfers seen to date are from initial centres to 
community programmes (Bedelu et al. 2007; Chan et al. 2010). As noted above, these urban 
centres probably had substantial unrecorded (silent) transfers with the rapid scale-up and 
decentralisation of ART services (Geng et al. 2010).
What are the implications of these data regarding community-based distribution of ARV 
drugs? Only four sites in this study had a system of community-based ARV drug 
distribution. These systems varied from models where patients only pick up their ARV 
drugs from a mobile point to models with mobile health posts with clinical check-up and 
adherence counselling. However, most of these programmes still depended heavily on the 
support of clinic-based staff for community-based ARV drug distribution.
Other models of community-based ART distribution, however, are emerging. In Rwanda, 
for example, Rich et al. reported a retention rate of 92.3% after 2 years using a model with 
intensive community-based treatment support that included ART distribution and directly 
observed ART by community health workers (Rich et al. 2012). Other programmes use 
trained HIV-infected peers (Community Care Coordinators) to visit ART patients monthly 
and perform a systematic symptom review and dispense ARV drugs (Wools-Kaloustian et 
al. 2009). In Mozambique, Medecins Sans Frontieres uses a Community ART model with 
stable ART patients who dispense monthly ART and provide adherence and social support 
to other ART clients in the community (Decroo et al. 2011). They reported retention rates of 
97.5% after a median follow-up time of 13 months. The effectiveness of community 
pharmacies where ART patients are trained to distribute ART at community distribution 
points needs to be confirmed by further research (MSF & UNAIDS 2012). Although these 
models are showing promising impact on retention, their feasibility and scalability still need 
to be evaluated.
The implementation of the current WHO guidelines (WHO 2013) aims to increase ART 
coverage and retention to save lives and to decrease HIV transmission. To achieve the 
ambitious goal of universal coverage in rural Africa, treatment will need to expand to serve 
communities beyond the reach of current clinics. The potential of decentralisation of ART 
delivery (through mobile clinics and community pharmacies) and community participation 
(through community health workers and the patients and their families) need to be explored 
further.
Koole et al. Page 9
Trop Med Int Health. Author manuscript; available in PMC 2016 January 25.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Besides misclassification of transfer to care to LTFU, there are other limitations to this 
study. Study sites were not randomly selected, and this could have introduced some 
selection bias. However, the selection (performed in 2006) was conducted in consultation 
with country-specific stakeholders and aimed to have a good balance of site characteristics 
that might influence retention and adherence. The intrinsic differences among countries (for 
example, in this study the majority of programmes with community-based distribution of 
ARV drugs and programmes supported by faith-based or non-governmental organisations 
were found in Uganda) could result in further confounding.
The strength of the current study is the use of consistent data collecting tools across diverse 
sites and the possibility of controlling for individual patient characteristics. By design, our 
research allowed studying interactions between programme level and individual 
characteristics, as illustrated by the differential effects of community-based distribution of 
ARV drugs between men and women. The design is less suited to study interactions between 
programme level characteristics or differences between countries.
Other limitations relate mainly to the constraints of retrospective chart review and the 
challenges of incomplete data (for example, WHO clinical stage and CD4 cell count) and the 
absence of certain variables at some of the sites (for example, distance to the clinic). The 
numbers of missing values for these variables are similar to numbers reported elsewhere 
(May et al. 2010). They highlight the importance of strengthening data collection systems to 
better respond and assess retention to care and treatment.
Because this was a retrospective chart review, other important structural predictors of 
retention, such as mode of transport, educational level and income, could not be assessed. 
The quality and completeness of the data varied among the study sites. Forster et al. (2008) 
found that poor quality data were associated with poor retention. In this study, the sites with 
a large proportion of missing records reported better retention proportions. While the 
significant association between the number of missing records and retention may indicate 
the presence of bias in this study, correcting for missing data did not change the conclusions. 
This indicates the robustness of the findings.
Conclusion
Patient retention to an individual programme worsened over time especially among males, 
younger persons and those with poor clinical indicators. Increased use of community 
programmes for ART drug dispensing could be considered for broader implementation.
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Figure 1. 
Kaplan-Meier estimates by site in Tanzania, Uganda and Zambia.
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Figure 2. 
Kaplan-Meier estimates by Community-Based Distribution (CBD) of ARVs in Tanzania, 
Uganda and Zambia.
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Table 1
Patient characteristics at ART initiation in multicountry retention study
Characteristic
Tanzania
(n = 1458)
Uganda
(n = 1472)
Zambia
(n = 1217)
Total number of
participants
(N = 4147)
Demographics
  Age (years): median (IQR) 37 (31–43) 35 (30–41) 35 (30–42) 36 (30–42)
    Age 18–29 years: n (%) 266 (18.2) 344 (23.4) 291 (23.9) 901 (21.7)
    Age ≥30 years: n (%) 1191 (81.7) 1122 (76.2) 923 (75.8) 3236 (78.0)
  Gender: n (%)
    Male 484 (33.2) 504 (34.2) 488 (40.1) 1476 (35.6)
    Female 974 (66.8) 968 (65.8) 728 (59.8) 2670 (64.4)
  Distance from clinic: n (%)
    <10 km 631 (43.3) 1073 (72.9) 212 (17.4) 1916 (46.2)
    10–25 km 251 (17.2) 185 (12.6) 15 (1.2) 451 (10.9)
    >25 km 461 (31.6) 139 (9.4) 13 (1.1) 613 (14.8)
    Missing 115 (7.9) 75 (5.1) 977 (80.3) 1167 (28.1)
ART related
  Year of ART initiation: n (%)
    2003–2004 36 (2.5) 54 (3.7) 51 (4.2) 141 (3.4)
    2005 232 (15.9) 226 (15.4) 188 (15.5) 646 (15.6)
    2006 278 (19.1) 229 (15.6) 278 (22.8) 785 (18.9)
    2007 287 (19.7) 337 (22.9) 336 (27.6) 960 (23.2)
    2008 360 (24.7) 296 (20.1) 212 (17.4) 868 (20.9)
    2009–2010 265 (18.2) 330 (22.4) 152 (12.5) 747 (18.1)
  Years of clinic operation prior to ART initiation: n (%)
    <1 year 286 (19.6) 183 (12.4) 72 (5.9) 541 (13.1)
    ≥1 to <2 years 312 (21.4) 196 (13.3) 196 (16.1) 704 (17.0)
    ≥2 to <3 years 272 (18.7) 325 (22.1) 305 (25.1) 902 (21.8)
    ≥3 to <4 years 341 (23.4) 304 (20.7) 277 (22.8) 922 (22.2)
    ≥4 to <5 years 196 (13.4) 207 (14.1) 211 (17.3) 614 (14.8)
    ≥5 years 51 (3.5) 257 (17.5) 156 (12.8) 464 (11.2)
  Prior ART experience: n (%) 112 (7.7) 85 (5.8) 55 (4.5) 252 (6.1)
  Prior exposure to NVP for PMTCT: n (%) 0 (0.0) 86 (8.9) 94 (12.9) 180 (6.7)
  Starting ART regimen: n (%)
    D4T-3TC-NVP 991 (68.0) 540 (36.7) 404 (33.2) 1935 (46.7)
    D4T-3TC-EFV 86 (5.9) 23 (1.6) 79 (6.5) 188 (4.5)
    ZDV-3TC-NVP 128 (8.8) 542 (36.8) 240 (19.7) 910 (21.9)
    ZDV-3TC-EFV 230 (15.8) 257 (17.5) 96 (7.9) 583 (14.1)
    TDF-3TC/FTC-NVP/EFV 7 (0.5) 93 (6.3) 354 (29.1) 454 (11.0)
    PI based 2 (0.1) 13 (0.9) 8 (0.7) 23 (0.6)
    Other 1 (0.1) 1 (0.1) 33 (2.7) 35 (0.8)
    Missing/non-sensical 13 (0.9) 3 (0.2) 3 (0.3) 19 (0.5)
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Characteristic
Tanzania
(n = 1458)
Uganda
(n = 1472)
Zambia
(n = 1217)
Total number of
participants
(N = 4147)
  CTX prophylaxis: n (%) 981 (67.3) 1186 (80.6) 724 (59.5) 2891 (69.7)
Clinical characteristics
  WHO clinical stage at start: n (%)
    WHO stage 1–2 301 (20.6) 639 (43.4) 394 (32.8) 1334 (32.2)
    WHO stage 3 539 (37.0) 508 (34.5) 553 (45.4) 1600 (38.6)
    WHO stage 4 325 (22.3) 160 (10.9) 112 (9.2) 597 (14.4)
    Missing 293 (20.1) 165 (11.2) 158 (13.0) 616 (14.9)
  Functional status: n (%)
    Working/active 748 (51.3) 904 (61.4) 488 (40.1) 2140 (51.6)
    Ambulatory 261 (17.9) 73 (5.0) 352 (28.9) 686 (16.5)
    Bedridden 31 (2.1) 13 (0.9) 71 (5.8) 115 (2.8)
    Missing 418 (28.7) 482 (32.7) 306 (25.1) 1206 (29.1)
Laboratory parameters
  CD4 (cells/µl): median (IQR) 133 (59–206) 136 (65–202) 134 (67–217) 134 (63–206)
    Missing: n (%) 337 (23.1) 303 (20.6) 366 (30.1) 1006 (24.3)
  TLC (cells/µl): median (IQR) 1700 (1100–3000) 1400 (980–1970) 1200 (500–1900) 1400 (900–2230)
    Missing: n (%) 903 (61.9) 1151 (78.2) 695 (57.1) 2749 (66.3)
  Haemoglobin (g/dl) 10.2 (8.9–11.8) 11.9 (10.5–13.2) 10.6 (9.0–12.1) 11.0 (9.5–12.5)
    Missing: n (%) 683 (46.8) 604 (41.0) 512 (42.1) 1799 (43.4)
Opportunistic infections
  Weight loss >10%: n (%) 310 (21.3) 96 (6.5) 435 (35.7) 841 (20.3)
  Chronic diarrhoea >1 month: n (%) 159 (10.9) 41 (2.8) 282 (23.2) 482 (11.6)
  Fever >1 month: n (%) 287 (19.7) 80 (5.4) 246 (20.2) 613 (14.8)
  Oral candidiasis: n (%) 103 (7.1) 76 (5.2) 90 (7.4) 269 (6.5)
  Wasting syndrome: n (%) 135 (9.3) 34 (2.3) 40 (3.3) 209 (5.0)
  Pulmonary TB: n (%) 171 (11.7) 151 (10.3) 169 (13.9) 491 (11.8)
ART, antiretroviral treatment; IQR, interquartile range; PMTCT, prevention mother-to-child transmission; NVP, nevirapine; 3TC, lamivudine; 
D4T, stavudine; ZDV, zidovudine; EFV, efavirenz; TDF, tenofovir, FTC, emtricitabine; PI, protease inhibitor; CTX, cotrimoxazole; TLC, total 
lymphocyte count; TB, tuberculosis.
Working/active: able to perform usual work in or out of the house; ambulatory: able to perform activities of daily living but not able to work; 
bedridden: not able to perform activities of daily living.
Wasting syndrome: weight loss of >10%, unexplained chronic diarrhoea >1 month and unexplained fever >1 month.
Data are missing for age and gender when the total number of patient was less than 4147.
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Table 2
Site characteristics in multicountry retention study
Characteristic
Tanzania
(n = 7)
Uganda
(n = 6)
Zambia
(n = 5)
Total
number of
sites
(N = 18)
General information
  Level of health facility
    National referral hospital 2 1 1 4
    Provincial/regional Hospital 2 0 2 4
    District hospital 3 1 2 6
    Primary/community-based health care 0 4 0 4
  Type of health facility
    Government 4 1 4 9
    Mission facility 3 1 1 5
    Non-religious NGO 0 4 0 4
  Setting
    Urban 4 5 3 12
    Rural/periurban 3 1 2 6
ART-related information
  Year ART was started at facility
    2003 1 2 2 5
    2004 3 2 3 8
    2005 2 2 0 4
    2006 0 0 0 0
    2007 1 0 0 1
  Number of adults currently on ARVs
    <2000 6 1 1 8
    2000–4000 1 4 1 6
    >4000 0 1 3 4
  Home-based care
    No 0 3 4 7
    Yes 7 3 1 11
  Physician-based care
    No 2 1 0 3
    Yes 5 5 5 15
ARV-dispensing characteristics
  Buddy needed for ART initiation
    No 0 0 3 3
    Yes 7 6 2 15
  Three counselling sessions needed for ART initiation
    No 1 2 1 4
    Yes 6 4 4 14
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Characteristic
Tanzania
(n = 7)
Uganda
(n = 6)
Zambia
(n = 5)
Total
number of
sites
(N = 18)
  Visit frequency after 6 months on ARVs
    Monthly 5 1 0 6
    Every 2 months 0 4 4 8
    Every 3 months 2 1 1 4
  Community-based distribution of ARVs
    No 7 3 4 14
    Yes 0 3 1 4
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Table 3
Community-based ARV drug distribution among study clinics in Tanzania, Uganda and Zambia
Community distribution of ARVs: any dispensing of ARVs happening outside the regular clinic, covering models where patients are
only picking up their ARV drugs from a mobile point to models with mobile health posts with clinical check-up and adherence
counselling
Programme and type of facility Activities
Programme 1: Non-governmental
organisation
Mobile clinic at community drug dispensing points on specific days
ARV drug and non-ARV drug pickup
Clinical investigation (patient monitoring), phlebotomy and adherence counselling
Referral of complicated cases
Programme 2: Faith-based
organisation
Mobile clinics at peripheral (non-ART) health centres and makeshift community clinics
on specific days
ARV drug and non-ARV drug pickup
Clinical investigation (patient monitoring), phlebotomy and adherence counselling
In addition: ARV drug distribution door to door to stable patients by community ART and
TB treatment supporters for specific patients (patients whose work/study schedule does not
allow them to visit the clinic)
Programme 3: Government Mobile clinics at peripheral (non-ART) health centres on specific days
ARV drug and non-ARV drug pickup
Referral for clinical investigations, phlebotomy and adherence counselling
Programme 4: Faith-based
organisation
Mobile clinics at peripheral (non-ART) health centres on specific days
ARV drug and non-ARV drug pickup
Clinical investigation (patient monitoring), phlebotomy and adherence counselling
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Table 6
Final multivariate model for predictors of attrition in multicountry retention study*
Adjusted hazard
ratio (95% CI)
Individual characteristics
  Age at start ART: <30 years (vs. ≥30 years) 1.30 (1.14, 1.47)
  WHO stage at start ART
    III vs. I & II 1.12 (0.95, 1.31)
    IV vs. I & II 1.56 (1.29, 1.88)
  Weight loss >10% 1.17 (1.00, 1.38)
  CD4 count (/log [tenfold] increase) 0.88 (0.78, 1.00)
  Functional status
    Ambulatory vs. working/active 1.29 (1.09, 1.54)
    Bedridden vs. working/active 1.54 (1.15, 2.07)
  Sex (men vs. women)
    In sites without community 1.33 (1.18, 1.50)
      ARV drug dispensing
    In sites with community 0.95 (0.67, 1.33)
      ARV drug dispensing
  Years of clinic operation by Type of health facility (/year)
    Government facility 1.17 (1.10, 1.23)
    Mission facility/non-religious NGO 1.03 (0.95, 1.11)
Programme characteristics
  ARV drug dispensing in community by Sex
    For women 0.55 (0.30, 1.01)
    For men 0.40 (0.21, 0.75)
  Type of health facility: Faith-based
facility or NGO vs. Government
(at start of the programme)
0.71 (0.42, 1.21)
ART, antiretroviral treatment; ARV, antiretroviral; CI, confidence interval; NGO: non-governmental organisation.
Working/active: able to perform usual work in or out of the house; ambulatory: able to perform activities of daily living but not able to work; 
bedridden: not able to perform activities of daily living.
*
The model was simplified using Akaike’s Information Criterion, retaining predictors and clinically plausible interaction terms that increased 
model fit, with a penalisation for increasing model complexity.
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